Judd Midlam brings a distinctive voice to contemporary fiction, blending scientific insight with literary depth.
United States
Joined March 2013
- Tweets711
- Following847
- Followers317
- Likes319
Pinned Tweet
SYNCOPE is featured in Kirkus Reviews magazine! See page 152, August 1, 2026: Volume XCIV, No. 15 issuu.com/kirkus-reviews/doc… via @issuu
Signed copies of my novel SYNCOPE are still on the shelf at Barnes & Noble Lake Nona (Mysteries & Thrillers, 6039 Lake Nona Blvd).
A psychological thriller about pharma, AI and free will. Kirkus: the novel “ultimately succeeds as an intimate study of a tortured soul finding redemption.”
Stop by and grab a signed copy while they last. #LakeNona #Orlando
Thanks @JoinTertulia for including Syncope in your Summer reading recommendations! Honored #indie :)
tertulia.com/editorial-list/…
Join me for a book signing of Syncope on Saturday, September 5 at Barnes & Noble Lake Nona! Come say hello, grab a signed copy, and chat about the book. I’d love to see you there.
Barnes & Noble Lake Nona
6039 Lake Nona Blvd, Orlando, FL
Event details: stores.barnesandnoble.com/ev…
#BarnesAndNoble #LakeNona #OrlandoEvents
Big pharma big bets in emerging psychedelics. This one, a DMT analogue.
fiercebiotech.com/biotech/el…
Syncope is now available, internationally, wherever books are sold. Buy a copy, sit somewhere nice, and enjoy responsibly. ☺️ 🙏 Cjmidlam.com
I'm so excited to share that SYNCOPE received the "Get It" Awards & Accolades Verdict along with a very well-done review!!! The novel is available in 5 days! See the Kirkus website for more: kirkusreviews.com/book-revie…
Pharma sector doubles down on AI amid hopes of slashing costs, timelines reuters.com/business/healthc…
#AIpharma, #AIRandD
What a fascinating agenda track - -
I’m looking forward to speaking at the @NIH WALS tomorrow ⚕️
I’ll be discussing our translational research to understand molecular mechanisms underlying addiction and related psychiatric risk relevant to potential treatment strategies.
💻 Tune in: oir.nih.gov/wals
Judd Midlam retweeted
I’m looking forward to speaking at the @NIH WALS tomorrow ⚕️
I’ll be discussing our translational research to understand molecular mechanisms underlying addiction and related psychiatric risk relevant to potential treatment strategies.
💻 Tune in: oir.nih.gov/wals
So good for Sunday vibes since ~2010. RMC BUDDHA-BAR Monte Carlo / Radio powered by Radio Monte Carlo radiomontecarlo.net/web-radi…
#neuroplastogens at scale is truly a fascinating idea
Psychedelic medicine has entered an entirely new era. 🧠🚀
What was once considered fringe science is now at the center of FDA discussions, White House policy initiatives, veteran mental health programs, and a rapidly growing biotech industry focused on neuroplasticity and precision psychiatry.
In this @ProgressPotent1 conversation, I sit down with
@EricSo168168, Co-Founder & Executive Chairman of
@Helus_Pharma, to explore:
• The rise of “next-generation” serotonergic agonists;
• Why psychedelic biotech is moving beyond psilocybin alone;
• The push for scalable neuroplasticity medicines;
• PTSD, depression, addiction & veteran mental health;
• FDA acceleration pathways and recent White House actions;
• Whether psychedelic therapies can realistically become standard of care;
We also discuss the broader evolution from counterculture psychedelics to mainstream pharmaceutical neuroscience - and the major scientific, regulatory, and commercial challenges still ahead.
#Psychedelics #MentalHealth #Neuroscience #Biotech #Psychiatry #PsychedelicMedicine #Neuroplasticity #HelusPharma #PrecisionPsychiatry #DepressionTreatment @rxMedyn @rxmedynamics
Judd Midlam retweeted
A single dose of #psilocybin was associated with rapid reduction in depressive symptoms in adults with major depressive disorder, with effects persisting beyond 3 months on secondary measures. ja.ma/4uhzmol
ALT RCT: Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression. Population: 14 Males, 21 Females, adults 20-65 y. Intervention: 35 Participants randomized, 17 Psilocybin, 18 Niacin. Findings: improvement in MADRS scores on day 8.
Judd Midlam retweeted
Applications are now open for the Public Leadership Institute (PLI) Political Leadership Track—a nonpartisan program designed for professionals and business leaders looking to better understand public policy, governance, and public leadership
Apply today: orlando.org/l/public-leaders…
Fun interview publishing today on writing fiction, about technology, when science is moving too fast! nonahoodnews.com/the-artist-…
Check out an interview from this week on the science divide -- writing about fiction and contemporary science, business, technology. nonahoodnews.com/the-artist-…
The pharmaceutical industry is embracing AI, but finding new drugs this way remains elusive. Drug companies like Eli Lilly and Roche are racing to build supercomputers to help fix the 90% failure rate in drug development
wsj.com/health/pharma/the-qu… via @WSJ
FDA commissioner says decision on psychedelic treatments will be out 'quickly' nbcnews.com/now/video/fda-co… via @nbcnews
